Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer

Background Modufolin® ([6R]-5,10-methylene tetrahydrofolate; [6R]-MTHF) is an endogenous biomodulator that is being developed as an alternative to leucovorin, a folate prodrug used in the treatment of colorectal cancer. The objective of this phase 1 dose de-escalation trial was to estimate the minim...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Gustavsson, Bengt, Carlsson, Göran, Swartling, Torbjörn, Kurlberg, Göran, Derwinger, Kristoffer, Björkqvist, Hillevi, Odin, Elisabeth, Gibson, Fernando
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2015
Soggetti:
Phase I Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4768212/
https://ncbi.nlm.nih.gov/pubmed/26189513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0272-0
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi